Concanavalin A (Con A) induces movement of its receptors on the cell surface membrane. This induction results in a concentration of Con A site complexes on one pole of the cell to form a cap. A marked difference was found in the mobility of Con A'receptors between lymphocytes from normal persons and lymphocytes from patients with Hodgkin's disease and other malignant lymphomas. Lymphocytes isolated-from tonsils of patients undergoing tonsillectomy and from axillary lymph nodes of breast cancer patients exhibited approximately 30% of cells with, caps, which is identical with the cap formation ability of normal lymphocytes. In biopsy material from patients with Hodgkin's disease 4nd other malignant lymphomas, a significant decrease in the ability of the lymphocytes to form caps was observed. This difference in the mobility of Con A sites was even more pronounced in lymphocytes isolated from the peripheral blood. In 123. patients with Hodgkin's disease and other malignant lymphomas, cap formation ranged between 3 and 12%. The ability of cells, from a bormal donor or a lyinphoma patient, to form caps was independent of the source from which the lymphocytes-were isolated, e.g., lymph node, spleen, or blood. Lymphocytes from patients with lymphoma were also agglutinated by Con A to a higher degree than normal lymphocytes. These findings are discussed in relation to the association of the lymphocytes with these malignancies and as a possible aid in their differential diagnosis.
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Concanavalin A (Con A) has been used as a probe to study changes in the mobility of specific receptors on the cell surface membrane (i-5) . Studies with this probe have shown differences in the structure and function of the surface membrane of normal and malignant cells (6) (7) (8) (9) . We have previously reported that lymphocytes from patients with chronic lymphocytic leukemia have a reduced cap-forming ability and a higher Con-A-induced agglutinability than normal lymphocytes (5) .
The present studies were undertaken in order: (1) to determine whether there are changes in the mobility of Con. A receptors on the surface of lymphocytes of patients with Hodgkin's disease and other lymphomas, (2) trations diluted in PBS was mixed with 0.5 ml of cell suspension to give a final concentration of 2 X 106 cells per ml in a 35 mm petri dish. The density and size of aggregates was scored in a scale from -to + + + + after 30 min. Incubation was carried out at 240 (6) . RESULTS Cap Formation with Fluorescent Concanavalin A of Lymphocytes from Biopsy Material of Patients with Malignant Lymphoma. Biopsy material was obtained from patients with various types of malignant lymphoma. All the patients were untreated and the biopsies were made in order to establish the histopathological diagnosis. The following patients were included in this series: 29 patients with active Hodgkin's disease, two patients with reticulum cell sarcoma, five with lymphosarcoma and four with non-Hodgkin's lymphoma. All biopsies were from affected lymph nodes and, in the great majority, these were cervical nodes. Lymphocytes were separated by the Ficoll-Hypaque method and examined for cap formation with F-Con A. In addition to the biopsies from the patients with malignant lymphoma, biopsy material was collected from non-lymphoma controls. These were tonsils from 19 patients undergoing tonsillectomy and axillary lymph nodes from six patients with breast cancer. Fig. 1 illustrates the results obtained with 100 /Ag/ml of F-Con A. Lymphocytes from all lymphoma patients exhibited a reduced ability to form caps with fluorescent Con A. This is true for patients with Hodgkin's disease, as well as for non-Hodgkin's lymphoma. The reduction in cap formation is even more pronounced in the patients with non-Hodgkin's lymphoma than in Hodgkin's disease. Lymphocytes isolated from tonsils of all the patients undergoing tonsillectomy and from lymph nodes of breast cancer patients exhibited a cap formation ability similar to that of normal lymphocytes (ref. 5 , and see also Fig. 2 ). The binding of F-Con A to both normal and lymphoma lymphocytes was inhibited -when a-methyl-Dmannopyranoside was added as a hapten inhibitor.
Ability of Lymphocytes from the Peripheral Blood of Patients with Hodgkin's Disease to Form Caps with Fluorescent Con A. Examination of lymphocytes from the peripheral blood of several new untreated patients with Hodgkin's disease revealed that their ability to form caps with fluorescent Con A is significantly reduced. Following this observation we extended this study to a large sample of Hodgkin's disease patients. In addition to the patients with Hodgkin's Disease, we included in this study a group of healthy donors as well as patients with various infections, autoimmune disorders, and other diseases.
Altogether, 118 patients with Hodgkin's disease and five cases with lymphosarcoma were included in the study. These constitute a very nonhomogeneous group of patients. They include patients of both sexes, aged 15-65 years; duration of illness from onset ranges between several weeks and 5 years. All patients were bled either prior to their first treatment or three or more months after they had completed a series of radio-or/and chemotherapy. Although all histological types of Hodgkin's disease are included, the majority are patients with nodular sclerosis and mixed cellularity.
The normal controls were samples fromi healthy blood donors aged 18-60 years. In this group are also included peripheral blood samples from three newborn babies. In the group designated as "other diseases" are included, as follows: one patient with infectious mononucleosis; 10 (-) and other malignant lymphoma, reticulum cell sarcoma (-), lymphosarcoma (A), and other undetermined types of sarcoma (V), from normal individuals (0), inflamed tonsils (0), cases of breast cancer (U), polycythemia vera (E), and pancytopenia (V). Lymphocytes were isolated from biopsy material or from peripheral blood. Fig. 2 shows the results of this study. Lymphocytes from all patients with Hodgkin's disease exhibit a significant reduction in the ability to form caps with fluorescent Con A. The great majority of the patients with Hodgkin's disease and the five patients with lymphosarcoma are within the range of 1-10% cap-forming ability. This is on the average even lower than the cap-forming ability of lymphocytes isolated from the lymph nodes of patients with Hodgkin's disease and other lymphoma. All healthy donors and patients with other diseases exhibited the pattern of cap formation of normal lymphocytes. (20) . Thus, much attention in Hodgkin's disease has been focused on the lymphocyte; many, though not all experimental and clinical observations support the view that the lymphocyte from patients with Hodgkin's disease functions abnormally (21) .
Binding of Fluorescent Con
The question which is then posed is: is there an association, in patients with Hodgkin's disease, between this abnormal behavior of the lymphocyte and the reduced cap-forming ability with Con A? This is not easy to establish. We thought that study of lymphocytes from certain autoimmune diseases would give us a clue to this problem, but all these patients turned out to behave as normal with this Con A probe. It seems that other avenues must be explored to resolve this question.
There are various possibilities of using the Con A probe in clinical practice. First, it can be used as an aid in the differential diagnosis between malignant lymphomas and other diseases. We have attempted to do so in a number of double blind tests with very promising results. However, there is room for more tests to be carried out by investigators other than ourselves. Another avenue which is worth exploring is the followup with the Con A probe of patients during remission. It may turn out that there are changes in the cap-forming ability during reactivation of disease symptoms. All these suppositions can and will now be experimentally tested.
